Added to YB: 2024-07-26
Pitch date: 2024-07-26
CLRB [bullish]
Cellectar Biosciences, Inc.
-95.32%
current return
Author Info
No bio for this author
Company Info
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States.
Market Cap
$9.2M
Pitch Price
$68.40
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.04
P/E
-0.29
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Investing Whisperer Stock Ideas - Cellectar Biosciences, Inc.
CLRB: Biotech with promising data for rare blood cancer (WM). Near 52-wk low due to warrant-heavy financing. Potential catalyst: FDA priority review late 2023. Funded, good data, tech crosses blood-brain barrier. Patience required, but significant upside potential if successful.
Read full article (1 min)